SARS-CoV-2 vaccination in patients with inflammatory bowel disease
© 2021 John Wiley & Sons Ltd..
BACKGROUND: The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions.
AIM: This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD.
METHODS: All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised.
RESULTS: Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited.
CONCLUSIONS: SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
GastroHep - 3(2021), 4 vom: 08. Juli, Seite 212-228 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prentice, Ralley E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ygh2.473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330811479 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330811479 | ||
| 003 | DE-627 | ||
| 005 | 20240403233609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ygh2.473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM330811479 | ||
| 035 | |a (NLM)34539248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prentice, Ralley E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 vaccination in patients with inflammatory bowel disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions | ||
| 520 | |a AIM: This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD | ||
| 520 | |a METHODS: All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised | ||
| 520 | |a RESULTS: Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a immunocompromised | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Rentsch, Clarissa |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ani, Aysha H |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Halliday, John |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Lewindon, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Connor, Susan J |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaly, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t GastroHep |d 2019 |g 3(2021), 4 vom: 08. Juli, Seite 212-228 |w (DE-627)NLM308979214 |x 1478-1239 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2021 |g number:4 |g day:08 |g month:07 |g pages:212-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ygh2.473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2021 |e 4 |b 08 |c 07 |h 212-228 | ||